Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 2,012,500 shares of its common stock at a price of $63.85 per share to the underwriter, which includes the exercise in full by the underwriter of its option to purchase 262,500 additional shares. The gross proceeds from the offering to Axonics, before deducting estimated offering expenses, were approximately $128.5 million. BofA Securities acted as the sole book-running manager for the offering. The shares described above were offered pursuant to a shelf reg(…) Read More »